Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Estefanell Tejero, A."'
Autor:
Pazo‐Oubiña, F.1, Estefanell‐Tejero, A.1, Riu‐Viladoms, G.1, Anglada‐Martínez, H.1, Molas‐Ferrer, G.1, Creus‐Baró, N.1
Publikováno v:
Journal of Clinical Pharmacy & Therapeutics. Apr2013, Vol. 38 Issue 2, p101-103. 3p.
Publikováno v:
Farmacia Hospitalaria. 36:434-437
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::744a3640f8593db6c2301edee6a87313
https://doi.org/10.1016/j.farma.2011.08.006
https://doi.org/10.1016/j.farma.2011.08.006
Autor:
Gloria, Molas-Ferrer, Dolors, Soy-Muner, Helena, Anglada-Martínez, Gisela, Riu-Viladoms, Anna, Estefanell-Tejero, Josep, Ribas-Sala
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 33(3)
mTOR (mammalian target of rapamycin) inhibitors sirolimus and everolimus, used as immunosuppressants in solid organ transplantation, may cause severe adverse effects, such as interstitial pneumonitis. INCIDENCE AND CLINICAL PRESENTATION: The estimate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e8e0b10b657821796be04dcaa0744b76
https://pubmed.ncbi.nlm.nih.gov/23712219
https://pubmed.ncbi.nlm.nih.gov/23712219
Publikováno v:
In Farmacia Hospitalaria September-October 2012 36(5):434-437
Autor:
Josep Ribas-Sala, Fernando do Pazo-Oubiña, Natàlia Creus-Baró, Gisela Riu-Viladoms, Anna Estefanell-Tejero, Helena Anglada-Martínez, Gloria Molas-Ferrer
Publikováno v:
International journal of clinical pharmacy. 34(6)
Background Zoledronic acid (ZA) is an intravenous bisphosphonate approved for the prevention and treatment of cancer skeletal-related events. Objective Our aim was to analyze the prescription patterns of ZA in the cancer outpatient clinic. Method We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e94099601a7396df7bbe4c3a756ce9b
https://pubmed.ncbi.nlm.nih.gov/22956210
https://pubmed.ncbi.nlm.nih.gov/22956210
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 36(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d357b265f32b797cc363df37720b7867
https://pubmed.ncbi.nlm.nih.gov/22871365
https://pubmed.ncbi.nlm.nih.gov/22871365
Autor:
MQ Gorgas Torner, L Ortiz Ruiz, A Estefanell Tejero, E Oliver Ferrer, L Borràs Trias, C. Pontes García, N Rudi Sola, L Raich Montiu, M De Castro Julve
Publikováno v:
European Journal of Hospital Pharmacy. 22:A109.1-A109
Background Tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) is a recently-marketed fixed-dose combination of antiretrovirals with which there is little clinical experience as yet. Purpose To describe our clinical experience with TDF/FTC/RPV, in term
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0a375c47891b1590d0c2d1c066db429
https://doi.org/10.1136/ejhpharm-2015-000639.262
https://doi.org/10.1136/ejhpharm-2015-000639.262
Publikováno v:
Medicina Clínica. 140:429-430
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60246ebd3ad2297cd8707388718c41fc
https://doi.org/10.1016/j.medcli.2012.11.022
https://doi.org/10.1016/j.medcli.2012.11.022
Publikováno v:
Medicina Clínica. 138:684-685
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e73ac8e5ae395e915579a66f9561cd8
https://doi.org/10.1016/j.medcli.2011.09.001
https://doi.org/10.1016/j.medcli.2011.09.001
Autor:
Anglada-Martínez, Helena, Pazo-Oubiña, Fernando, Molas-Ferrer, Glòria, Estefanell-Tejero, Anna, Riu-Viladoms, Gisela, Ribas-Sala, Josep, Creus-Baró, Natàlia
Publikováno v:
International Journal of Clinical Pharmacy; Dec2012, Vol. 34 Issue 6, p832-836, 5p